All GLP-1 plans include a six-month money-back guarantee
Their role extends far beyond flavour
The prior authorization systems, formulary management platforms, and electronic health record integrations that sit between a clinicians prescribing decision and a patient filling a prescription were not designed for a drug class of this complexity, this volume, or this clinical significance
(2025) T2DM: 47.3% reinitiated GLP-1 therapy within 1 year of discontinuation 57.3% reinitiated within 2 years Without T2DM: 36.3% reinitiated within 1 year 46.4% reinitiated within 2 years Key Factors Linked to Reinitiation: Patients age 65 years Less likely to reinitiate Weight regain after discontinuation Higher likelihood of restarting therapy Moderate to severe GI side effects during initial treatment Lower likelihood of reinitiation Main Takeaway: Most patients who initiated GLP-1 therapy stopped within one year, with higher discontinuation rates among those without T2DM
Nasal spray protocol: Dose: 200-500 mcg per application Frequency: 1 to 2 times daily Duration: 4 to 8 weeks Nasal delivery is particularly interesting for researchers focused on neurological applications, as the nasal route provides a potential pathway to bypass the blood-brain barrier through the olfactory and trigeminal nerve pathways
Weight Regain Risk Increases Studies published in medical journals show that many people regain a portion of their lost weight when stopping quickly without a plan